United Therapeutics Corporation to Post Q3 2017 Earnings of $3.79 Per Share, Wedbush Forecasts (UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at Wedbush boosted their Q3 2017 EPS estimates for shares of United Therapeutics Corporation in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will earn $3.79 per share for the quarter, up from their prior estimate of $3.77. Wedbush has a “Outperform” rating and a $213.00 price objective on the stock. Wedbush also issued estimates for United Therapeutics Corporation’s Q4 2017 earnings at $3.51 EPS, Q1 2018 earnings at $3.61 EPS, Q2 2018 earnings at $3.15 EPS, Q3 2018 earnings at $3.31 EPS and Q4 2018 earnings at $3.28 EPS.
United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The business had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.42 EPS. TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/09/united-therapeutics-corporation-to-post-q3-2017-earnings-of-3-79-per-share-wedbush-forecasts-uthr.html.
A number of other analysts have also issued reports on UTHR. J P Morgan Chase & Co set a $125.00 price objective on shares of United Therapeutics Corporation and gave the company a “hold” rating in a research note on Tuesday, April 11th. Jefferies Group LLC reiterated a “sell” rating and set a $116.00 price objective on shares of United Therapeutics Corporation in a research note on Wednesday, April 12th. HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a research note on Monday, April 17th. Cowen and Company reiterated a “hold” rating and set a $121.00 price objective on shares of United Therapeutics Corporation in a research note on Wednesday, April 26th. Finally, ValuEngine lowered shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Six investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. United Therapeutics Corporation currently has a consensus rating of “Hold” and an average price target of $134.50.
United Therapeutics Corporation (NASDAQ UTHR) opened at 131.04 on Tuesday. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The company has a 50 day moving average of $130.70 and a 200-day moving average of $136.13. The firm has a market cap of $5.69 billion, a PE ratio of 15.20 and a beta of 1.51.
United Therapeutics Corporation declared that its board has approved a share repurchase program on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 4.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.
In other news, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $119.40, for a total transaction of $151,041.00. Following the completion of the sale, the chief executive officer now owns 1,405 shares of the company’s stock, valued at $167,757. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Giltner sold 3,490 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $131.12, for a total transaction of $457,608.80. The disclosure for this sale can be found here. Insiders have sold 23,758 shares of company stock valued at $3,058,699 in the last three months. Corporate insiders own 7.80% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in UTHR. First Midwest Bank Trust Division acquired a new position in United Therapeutics Corporation during the first quarter worth approximately $1,057,000. Dock Street Asset Management Inc. increased its position in United Therapeutics Corporation by 21.5% in the first quarter. Dock Street Asset Management Inc. now owns 35,455 shares of the biotechnology company’s stock worth $4,800,000 after buying an additional 6,280 shares in the last quarter. Meritage Portfolio Management increased its position in United Therapeutics Corporation by 1.3% in the first quarter. Meritage Portfolio Management now owns 37,801 shares of the biotechnology company’s stock worth $5,117,000 after buying an additional 502 shares in the last quarter. Profund Advisors LLC increased its position in United Therapeutics Corporation by 0.8% in the first quarter. Profund Advisors LLC now owns 24,714 shares of the biotechnology company’s stock worth $3,346,000 after buying an additional 187 shares in the last quarter. Finally, Korea Investment CORP increased its position in United Therapeutics Corporation by 1.6% in the first quarter. Korea Investment CORP now owns 97,700 shares of the biotechnology company’s stock worth $13,227,000 after buying an additional 1,500 shares in the last quarter.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.